U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT06811844) titled 'Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC' on Jan. 25.
Brief Summary: This prospective, phase II, multicenter, randomized controlled study aims to compare the complete response rate and long-term survival outcomes of two-cycle and three-cycle induction therapy with modified TPF regimens combined with camrelizumab in patients with locally advanced nasopharyngeal carcinoma.
Study Start Date: Feb. 01
Study Type: INTERVENTIONAL
Condition:
Nasopharyngeal Neoplasms
PD-1 Inhibitor
Induction Therapy
Complete Response
Chemotherapy
Intervention:
DRUG: Two-cycle induction che...